Latest Immunosuppressive drug Stories
ADDISON, Texas, April 21 /PRNewswire/ -- The International Society for Heart and Lung Transplantation (ISHLT) today announces new guidelines to standardize care for heart transplant patients worldwide.
Sirolimus-based immunosuppression and radiofrequency ablation are promising treatments for HCC.
The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.
Test could lead to tailored treatment for patients at highest risk.
People need longer-term support than most friends, relatives or health care professionals realize.
Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.
A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy.
Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC).
AST Delivers Letter to Senate Leadership WASHINGTON, Oct.